Chief Scientist

Cannabinoid and endocannabinoid research indicates promising, predominantly preclinical, tumour-directed anticancer effects across human and canine models, particularly for CBD and THC, often in combination with conventional therapies. For supportive care, human clinical evidence strongly supports the use of cannabinoids for chemotherapy-induced nausea and vomiting (CINV) and pain, with emerging data for neuropathy and anxiety. Canine studies are beginning to explore safety and pharmacokinetics in a clinical context. Feline research, however, lacks direct cannabinoid-cancer intervention evidence, representing a significant gap.